increased RhoGDIb mRNA stability which then promotes invasion. Indeed, inhibition of ATG7-mediated autophagy led to AUF1 protein accumulation, RhoGDIb downregulation and decreased cell invasion.
INTRODUCTION AND OBJECTIVES: Despite cisplatin-based chemotherapy (CT) is recommended in MIUBC, an unmet need is to identify new drugs or combinations to improve the outcomes. SGC combination was evaluated in an open-label, single-arm, phase 2 trial (NCT01222676).
METHODS: After TURB, pts with T2-T4a N0 MIUBC received 4 cycles of cisplatin 70 mg/m2 d1, gemcitabine 1000 mg/m2 d1 and 8, q3 wks. Sorafenib 400 mg q12h was administered daily from day 1 until radical cystectomy. In a Simon 0 s 2-stage design, the primary endpoint was pathologic complete responses (pT0). Residual carcinoma in situ was considered pT0. ITT analysis was applied. Statistical hypothesis assumed H0: 0.20 and H1: 0.40 (a and b of 5% and 10%). ERCC1 immunohistochemistry (IHC) and next-generation sequencing (NGS) of TURB tissue, and measurement of baseline circulating VEGF levels, were planned.
RESULTS: From 04/2011-06/2016, 45 pts were enrolled. 28 pts (62.2%) had macroscopical residual disease after TURB, 17 (37.8%) presented with clinical stage T3-4. pT0 was obtained in 19 pts (42.2%, 95%CI: 27.6-57.9); pT1 in 24 (53.3%, 95%CI: 37.9-68.3). After median follow-up of 35 months, median PFS was not reached (IQR: 29.4-NE), like median OS (IQR: 30.3-NE). Pathological response (pT0 vs pT1 vs other) predicted for both PFS (p¼0.015) and OS (p¼0.046). Hematologic (hem) G3-4 adverse events (AE): platelet 28.9%, neutrophils 15.6%, Hb (4.4%). Extra-hem AEs were seen in 9 pts (20%). 24 (53.3%) pts needed S temporary interruption (5 cases discontinuation).Tumor samples were available from 23 pts for ERCC1-IHC, 24 for NGS: ERCC1 IHC expression was associated with non response (pT2, p¼0.033). ERBB2/ERBB3 mutations were found only in responders (pT1, 20%). PIK3CA/AKT mutations (missense, and newly-identified mutations) were more frequent in pT2 pts (35.7% vs 20%) . Baseline VEGF levels did not predict for PFS/OS. NGS of the remaining pts of the trial is ongoing.
CONCLUSIONS: SGC combination was active and effective in MIUBC. Translational analyses are providing information to develop combination of CT with new more potent and selective TKIs, possibly in more selected pts. (MIBC) is recognized as the standard of care, the management of patients with locally advanced and/or nodal disease after NAC and radical cystectomy (RC) is not well defined. We sought to evaluate the association of adjuvant chemotherapy (AC) and overall survival (OS) among patients with adverse pathology after NAC and RC.
METHODS: The National Cancer Database was reviewed to identify patients with adverse pathology (pT3N0, pT4N0, or pTanyN1-3) at RC following NAC from 2006-2012. Patients were stratified by receipt of AC. Clinical and pathologic variables were abstracted. OS was the primary end-point and differences on the basis of AC receipt among all patients and as stratified by pathologic stage were assessed by the Kaplan-Meier method and log-rank test. Multivariable Cox proportional hazards regression was used to assess the association of AC with OS controlling for age, sex, race, Charlson score, year of diagnosis, pathologic stage, and receipt of adjuvant radiotherapy.
RESULTS: Adverse pathology following NAC and RC was identified in 1,361 patients from 2006-2012, of whom 328 (24.1%) received AC. Staging was pT3N0 in 444 (32.6%), pT4N0 in 162 (11.9%), and pTanyN1-3 in 755 (55.5%). Median OS for the entire cohort was 22.9 months, which differed by pathologic stage: 34.6 months (pT3N0), 21.4 months (pT4N0), and 19.3 months (pTanyN1-3) (p<0.01). No difference in OS was noted by receipt of AC in the overall cohort (median OS 24.6 months with AC vs 22.0 months without AC; p¼0.18), or when stratified by pathologic stage. On multivariable analysis, receipt of AC was not significantly associated with overall mortality (HR 0.86; 95%CI 0.74-1.01; p¼0.06) for all patients. When stratified by stage, AC was associated with a significantly decreased risk of mortality among patients with pT4N0 disease (HR 0.56; 95%CI 0.33-0.97; p¼0.04), but not pT3N0 or pTanyN1-3 (p>0.05).
CONCLUSIONS: Patients with adverse pathology at RC after NAC have a median OS of approximately 2 years. AC was not associated with improved survival, except in the subgroup with pT4N0 disease. Clinical trials with newer systemic therapies are warranted for patients in this setting. INTRODUCTION AND OBJECTIVES: Neoadjuvant chemotherapy is considered the standard of care in patients with muscleinvasive bladder cancer (MIBC) and has been shown to confer overall survival advantages of 5% in RCTs. Data on neoadjuvant chemotherapy (NAC) administration rates in patients undergoing robot-assisted radical cystectomy (RARC) is limited, ranging from 0 to 31% in the published literature. We report administration rates of NAC from a multi-institutional European database focusing on the centres performing totally intracorporeal RARC. Reporting the effect of NAC on down-staging and upstaging rates from clinical staging (cT) to the pathological specimen (pT).
METHODS: Retrospective review of the prospectively populated multi-institutional database identified 717 patients at 9 different Institutions (6 countries), with a minimum of 12 months follow-up, who underwent RARC for non-metastatic bladder cancer with curative intent between Dec 2003 and March 2015. Clinical stage was assigned based on a combination of specimen pathology from TURBT, EUA and imaging studies. Cisplatin based NAC was offered to patients with cT2-cT4, taking into account patient performance status. Clinical staging, pathologic staging and survival data at the latest follow-up were collected.
RESULTS: Median age was 68 years, 78% were men. 95.2% of patients had TCC. 532 (74.2%) patients were alive at the time of the analysis. The median follow-up time for patients was 31 months . 465 patients (65%) had cT2-T4 TCC. In this series 25.3% of patients received NAC. See table 1 for upstaging and down-staging related to NAC. PSM rates were associated with upstaging (p<0.001). On multivariable analysis NAC was associated with down-staging in all patients OR 3.46 95% CI 2.34-5.13 p <0.001 and this effect increased in patients with non-organ confined disease OR 5.45 95%CI 2.15-13.8 p<0.001. The 5-year CSS, OS and RFS were 69.9%, 66.1% and 66.3% respectively. On multivariable analysis, pathological non-organ confined versus organ confined disease was found to impact CSS, OS and RFS (HR 4.4, 3.8 and 3.8 respectively).
CONCLUSIONS: NAC was associated with downstaging of MIBC. Increasing NAC administration rates would likely further improve oncological outcomes.
Source of Funding: None

MP34-16 COULD ADJUVANT CHEMOTHERAPY HAVE THERAPEUTIC BENEFIT AFTER NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH EQUAL TO OR GREATER THAN PT3 MUSCLE INVASIVE BLADDER CANCER?
INTRODUCTION AND OBJECTIVES: Neoadjuvant chemotherapy (NAC) has been associated with improved prognosis in muscle invasive bladder carcinoma (MIBC) patients. However, the therapeutic effect of adjuvant chemotherapy (AC) following NAC remains unknown.
METHODS: We retrospectively identified 576 patients who were treated by radical cystectomy for MIBC at our 7 institutions between 2007 and 2014. Among them, 196 patients with MIBC that was equal to or greater than pT3 were included in the present analysis. We compared the clinical characteristics and outcomes between MIBC patients with and without AC.
RESULTS: Overall, 65 patients (33.2%) were treated by AC. The mean age of the patients with AC (AC group) was 65.9 years, which was significantly lower than that in their counterparts (73.7 years, p<0.001). The AC group had a higher incidence of pathological lymph node positive and concomitant CIS than their counterparts (p¼0.002, p¼0.018, respectively). The 5-year overall survival rate for the AC group was 46.0%, which was significantly higher than their counterparts (31.2%, p¼0.03). Multivariate analysis revealed that the absence of AC (hazard ratio: HR, 1.93, p¼0.015) was an independent indicator for death in addition to lymphovascular invasion (HR, 2.06, p¼0.002) and pathological lymph node positive (HR, 1.9, p¼0.011). In the subgroup of patients without NAC (N¼139), 43 patients (30.9%) were treated by AC. The mean age of patients in the AC group was 65.3 years, which was significantly lower than that in their counterparts (74.9 years, p<0.001). The AC group had a higher incidence of pathological lymph node positive than their counterparts (p¼0.006). The 5-year overall survival rate for the AC group was 47.5%, which was significantly higher than that in their counterparts (29.4%, p¼0.015). Multivariate analysis revealed that the absence of AC (hazard ratio: HR, 2.16, p¼0.028) was an independent indicator for death in addition to pathological lymph node positive (HR, 1.98, p¼0.025). In the subgroup of patients with NAC (N¼57), 22 patients (38.6%) were treated by AC. The 5-year overall survival rate for the AC group (40.2%) was not significantly higher than that in their counterparts (36.0%, p¼0.932).
CONCLUSIONS: In MIBC patients with a pathological stage equal to or greater than pT3, AC seems to be associated with a better prognosis. However, our data does not support the addition of AC to patients previously treated with NAC.
Source of Funding: none
MP34-17
PROGNOSTIC SIGNIFICANCE OF SERUM g-GLUTAMYLTRANSFERASE IN ADVANCED UROTHELIAL CARCINOMA PATIENTS Hiroshi Fukushima*, Yasukazu Nakanishi, Madoka Kataoka, Ken-ichi Tobisu, Fumitaka Koga, Tokyo, Japan INTRODUCTION AND OBJECTIVES: g-glutamyltransferase (GGT), which is expressed in various human cancer cells, is known as a membrane-bound enzyme playing a protective role from oxidative stress. Recent studies indicated that GGT can also exert pro-oxidant effects at the membrane surface and the extracellular microenvironment, contributing to the regulation of proliferative/apoptotic balance, the acquisition of chemo-resistance, and cancer progression. Here, we Vol. 197, No. 4S, Supplement, Saturday, May 13, 2017 THE JOURNAL OF UROLOGY â e433
